Patents Assigned to OcuTerra Therapeutics, Inc.
  • Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives
    Patent number: 11858900
    Abstract: The application relates to 2-amino-4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: January 2, 2024
    Assignee: OcuTerra Therapeutics, Inc.
    Inventors: D. Scott Edwards, Ben C. Askew, Takeru Furuya
  • Fluorinated integrin antagonists
    Patent number: 11685737
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: June 27, 2023
    Assignee: OcuTerra Therapeutics, Inc.
    Inventors: Ben C. Askew, Richard W. Heidebrecht, Takeru Furuya, Mark E. Duggan, D. Scott Edwards
  • Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
    Patent number: 11685738
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: June 27, 2023
    Assignee: OcuTerra Therapeutics, Inc.
    Inventors: Ben C. Askew, Takeru Furuya